Revelation Biosciences, Inc.

NasdaqCM:REVB Stock Report

Market Cap: US$3.2m

Revelation Biosciences Valuation

Is REVB undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of REVB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate REVB's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate REVB's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for REVB?

Key metric: As REVB is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for REVB. This is calculated by dividing REVB's market cap by their current book value.
What is REVB's PB Ratio?
PB Ratio1.2x
BookUS$2.67m
Market CapUS$3.21m

Price to Book Ratio vs Peers

How does REVB's PB Ratio compare to its peers?

The above table shows the PB ratio for REVB vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average0.8x
PALI Palisade Bio
0.5x-36.4%US$3.2m
ONCR Oncorus
0.1xn/aUS$3.3m
GRTS.Q Gritstone bio
0.2x-2.0%US$3.7m
OGEN Oragenics
2.4xn/aUS$3.7m
REVB Revelation Biosciences
1.2xn/aUS$3.2m

Price-To-Book vs Peers: REVB is expensive based on its Price-To-Book Ratio (1.2x) compared to the peer average (0.8x).

Price to Book Ratio vs Industry

How does REVB's PB Ratio compare vs other companies in the US Biotechs Industry?

59 CompaniesPrice / BookEstimated GrowthMarket Cap
GRAL GRAIL
0.2x35.7%US$588.69m
AMRN Amarin
0.4x-7.7%US$205.50m
IMAB I-Mab
0.4x1.8%US$76.61m
MGX Metagenomi
0.3x-23.2%US$75.22m
REVB 1.2xIndustry Avg. 1.9xNo. of Companies73PB01.63.24.86.48+
59 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: REVB is good value based on its Price-To-Book Ratio (1.2x) compared to the US Biotechs industry average (1.9x).

Price to Book Ratio vs Fair Ratio

What is REVB's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

REVB PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio1.2x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate REVB's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst REVB forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$0.76
US$12.75
+1,588.7%
56.9%US$20.00US$5.50n/a2
Nov ’25US$0.82
US$14.45
+1,655.8%
38.4%US$20.00US$8.90n/a2
Oct ’25US$0.84
US$14.45
+1,623.7%
38.4%US$20.00US$8.90n/a2
Sep ’25US$1.15
US$16.95
+1,373.9%
47.5%US$25.00US$8.90n/a2
Aug ’25US$1.48
US$18.70
+1,163.5%
33.7%US$25.00US$12.40n/a2
Jul ’25US$1.87
US$18.70
+900.0%
33.7%US$25.00US$12.40n/a2
Jun ’25US$1.93
US$18.70
+868.9%
33.7%US$25.00US$12.40n/a2
May ’25US$2.15
US$32.13
+1,394.2%
22.2%US$39.25US$25.00n/a2
Apr ’25US$2.66
US$32.13
+1,107.7%
22.2%US$39.25US$25.00n/a2
Feb ’25US$3.18
US$244.63
+7,592.6%
84.0%US$450.00US$39.25n/a2
Jan ’25US$15.02
US$343.50
+2,186.8%
31.0%US$450.00US$237.00n/a2
Dec ’24US$22.80
US$343.50
+1,406.6%
31.0%US$450.00US$237.00n/a2
Nov ’24US$18.39
US$343.50
+1,767.9%
31.0%US$450.00US$237.00US$0.822
Oct ’24US$20.68
US$343.50
+1,560.9%
31.0%US$450.00US$237.00US$0.842
Sep ’24US$20.25
US$343.50
+1,596.3%
31.0%US$450.00US$237.00US$1.152
Aug ’24US$25.19
US$343.50
+1,263.6%
31.0%US$450.00US$237.00US$1.482
Jul ’24US$28.20
US$343.50
+1,118.1%
31.0%US$450.00US$237.00US$1.872

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

ANI Pharmaceuticals

US$1.1b

A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.

ANIP

US$57.86

7D

3.9%

1Y

15.0%

Teva Pharmaceutical Industries

US$18.9b

Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.

TEVA

US$16.59

7D

-1.3%

1Y

69.3%

Collegium Pharmaceutical

US$993.0m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

COLL

US$31.19

7D

4.8%

1Y

22.3%